Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 101 to 150 of 163 results for metastatic breast cancer

  1. Eribulin for the treatment of locally advanced or metastatic breast cancer (TA250)

    This guidance has been updated and replaced by NICE technology appraisal guidance 423 and NICE technology appraisal guidance 515.

    Technology appraisal guidance
    Published
    3 April 2012

  2. MammaTyper in vitro diagnostic test for determining breast cancer subtypes (MIB135)

    NICE has developed a medtech innovation briefing (MIB) on the MammaTyper in vitro diagnostic test for determining breast cancer subtypes .

    Medtech innovation briefing
    Published
    18 January 2018

  3. Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]

    Discontinued [GID-TA10570]

    Technology appraisal guidance
    Discontinued

  4. Guidance on the use of capecitabine for the treatment of locally advanced or metastatic breast cancer (TA62)

    This appraisal has been updated and replaced by NICE guideline CG81.

    Technology appraisal guidance
    Published
    28 May 2003

  5. Axxent electronic brachytherapy system for early stage breast cancer (MIB76)

    NICE has developed a medtech innovation briefing (MIB) on Axxent electronic brachytherapy system for early stage breast cancer

    Medtech innovation briefing
    Published
    24 August 2016

  6. Endoscopic mastectomy and endoscopic wide local excision for breast cancer (IPG296)

    Evidence-based recommendations on endoscopic mastectomy and endoscopic wide local excision for breast cancer. This involves removing part or all of the breast using special instruments inserted through small cuts in the skin (keyhole surgery).

    Interventional procedures guidance
    Published
    22 April 2009
    View recommendations

    Sections for IPG296

  7. Brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision (IPG268)

    Evidence-based recommendations on brachytherapy as the sole method of adjuvant radiotherapy for breast cancer after local excision. This involves inserting radioactive sources into the space in the breast where tissue has been removed to minimise the chances of the cancer coming back.

    Interventional procedures guidance
    Published
    23 July 2008
    View recommendations

    Sections for IPG268

  8. Interstitial laser therapy for breast cancer (IPG89)

    Evidence-based recommendations on interstitial laser therapy for breast cancer. This involves using laser energy to destroying the cancer cells.

    Interventional procedures guidance
    Published
    22 September 2004
    View recommendations

    Sections for IPG89

  9. Image-guided radiofrequency excision biopsy of breast lesions (IPG308)

    Evidence-based recommendations on image-guided radiofrequency excision biopsy of breast lesions. This involves inserting a probe that uses radiofrequency energy to cut through the breast internally, and removing the lump with a small area of surrounding tissue to test for cancer.

    Interventional procedures guidance
    Published
    22 July 2009
    View recommendations

    Sections for IPG308

  10. Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433

    Awaiting development [GID-TA11489] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)

    NICE has developed a medtech innovation briefing (MIB) on Signatera for detecting molecular residual disease from solid tumour cancers .

    Medtech innovation briefing
    Published
    4 October 2022

  12. Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID 5072]

    Awaiting development [GID-TA10960] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Endoscopic axillary lymph node retrieval for breast cancer (IPG147)

    Evidence-based recommendations on endoscopic axillary lymph node retrieval for breast cancer. This involves using narrow instruments to remove the lymph nodes through small, rather than large, openings to reduce the risk of infection and other problems.

    Interventional procedures guidance
    Published
    14 December 2005
    View recommendations

    Sections for IPG147

  14. Artificial intelligence in mammography (MIB242)

    NICE has developed a medtech innovation briefing (MIB) on artificial intelligence in mammography .

    Medtech innovation briefing
    Published
    5 January 2021

  15. Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane (TA371)

    This guidance has been updated and replaced by NICE technology appraisal guidance 458.

    Technology appraisal guidance
    Published
    16 December 2015

  16. Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]

    In development [GID-TA11022] Expected publication date: TBC

    Technology appraisal guidance
    In development

  17. Everolimus for advanced renal cell carcinoma after previous treatment (TA432)

    Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment.

    Technology appraisal guidance
    Published
    22 February 2017
    View recommendations

    Sections for TA432

  18. Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]

    Awaiting development [GID-TA11487] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  19. Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update): draft scope consultation

    We are listening to your views on this NICE guideline. Comments close 19 April 2024.

    NICE guideline
    In consultation

  20. Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)

    In development [GID-TA10261] Expected publication date: TBC

    Technology appraisal guidance
    In development

  21. Surgery to the breast:- What is the optimum tumour-free margin width after breast-conserving surgery for women with ductal carcinoma in situ (DCIS) and invasive breast cancer?

    NG101/1 Question Surgery to the breast:- What is the optimum tumour-free margin width after breast-conserving surgery for...

    Research recommendation
    Published
    11 December 2018

  22. Effectivness of 26 Gy in 5 fractions over 1 week regimen in people receiving breast construction- What is the effectiveness of radiotherapy given in 26 Gy in 5 fractions over 1 week compared with 40 Gy in 15 fractions over 3 weeks in people with early or locally advanced invasive breast cancer who are offered breast reconstruction?

    Effectivness of 26 Gy in 5 fractions over 1 week regimen in people receiving breast construction- What is the effectiveness of...

    Research recommendation
    Published
    7 August 2023

  23. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together TS ID 11781

    Awaiting development [GID-TA11110] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  24. Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA579)

    This guidance has been replaced by NICE's technology appraisal guidance on abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy.

    Technology appraisal guidance
    Published
    8 May 2019

  25. What is the adherence to, and satisfaction with, different intervention formats (for example, individual, group, virtual, and face to face) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the impact of greater adherence on effectiveness for different groups, such as: women, men, trans people and non-binary people people from minority ethnic family backgrounds people with learning disabilities or cognitive impairment, or physical disabilities, or both neurodiverse people?

    virtual, and face to face) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the...

    Research recommendation
    Published
    5 May 2023

  26. What is the adherence to, and satisfaction with, different intervention formats (for example, individual, group, virtual, and face to face) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the impact of greater adherence on effectiveness for different groups, such as: women, men, trans people and non-binary people people from minority ethnic family backgrounds people with learning disabilities or cognitive impairment, or physical disabilities, or both neurodiverse people?

    virtual, and face to face) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the...

    Research recommendation
    Published
    7 August 2023

  27. Efectiveness of 26 Gy in 5 fractions over 1 week regimen in people receiving nodal irradiation- What is the effectiveness of radiotherapy given in 26 Gy in 5 fractions over 1 week compared with 40 Gy in 15 fractions over 3 weeks in people with early or locally advanced invasive breast cancer who are also offered nodal irradiation?

    fractions over 3 weeks in people with early or locally advanced invasive breast cancer who are also offered nodal...

    Research recommendation
    Published
    7 August 2023

  28. What is the most effective and cost-effective way of delivering the intervention (for example, type of physiotherapy or exercise, mode of delivery, number of sessions) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the acceptability of the intervention for different groups, such as: women, men, trans people and non-binary people people from minority ethnic family backgrounds people with learning disabilities or cognitive impairment, or physical disabilities, or both neurodiverse people?

    delivery, number of sessions) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is...

    Research recommendation
    Published
    5 May 2023

  29. Strategies to reduce arm and shoulder problems- What is the most effective and cost-effective way of delivering the intervention (for example, type of physiotherapy or exercise, mode of delivery, number of sessions) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is the acceptability of the intervention for different groups, such as: women, men, trans people and non-binary people people from minority ethnic family backgrounds people with learning disabilities or cognitive impairment, or physical disabilities, or both neurodiverse people?

    delivery, number of sessions) to reduce arm and shoulder problems after breast cancer surgery or radiotherapy, and what is...

    Research recommendation
    Published
    7 August 2023

  30. Neoadjuvant endocrine therapy in premenopausal women:- Is neoadjuvant endocrine therapy safe in premenopausal women with early breast cancer?

    neoadjuvant endocrine therapy safe in premenopausal women with early breast cancer? Any explanatory notes(if applicable) To...

    Research recommendation
    Published
    11 December 2018

  31. Interim process and methods guide for the clinical guideline updates using standing committees pilot programme 2013 (PMG17)

    Interim process and methods guide for the clinical guideline updates using standing committees pilot programme 2013

  32. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165]

    In development [GID-TA11318] Expected publication date: TBC

    Technology appraisal guidance
    In development

  33. Neoadjuvant treatment:- What are the indications for postmastectomy radiotherapy after neoadjuvant chemotherapy?

    guidance details Comes from guidance Early and locally advanced breast cancer: diagnosis and management Number...

    Research recommendation
    Published
    11 December 2018

  34. Breast reconstruction:- What are the long-term outcomes for breast reconstruction in women having radiotherapy to the chest wall?

    Recommendation ID NG101/3 Question Breast reconstruction:- What are the long-term outcomes for breast reconstruction in...

    Research recommendation
    Published
    11 December 2018

  35. Neoadjuvant endocrine therapy in postmenopausal women:- Is there a benefit for neoadjuvant endocrine therapy in postmenopausal women with early breast cancer?

    for neoadjuvant endocrine therapy in postmenopausal women with early breast cancer? Any explanatory notes(if applicable) To...

    Research recommendation
    Published
    11 December 2018

  36. What is the role of arm and shoulder specific exercises compared with and/or used as an adjunct to established lymphoedema treatments (such as compression garments and complex decongestive therapy)?

    measures. Source guidance details Comes from guidance Advanced breast cancer: diagnosis and treatment Number...

    Research recommendation
    Published
    6 July 2015

  37. Etirinotecan pegol for treating breast cancer with brain metastases [ID881]

    Discontinued [GID-TA10066]

    Technology appraisal guidance
    Discontinued

  38. NICE real-world evidence framework (ECD9)

    The NICE real-world evidence framework aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence

  39. NICE publishes final draft guidance on Enhertu after commercial discussions conclude without a price to make it a cost-effective use of NHS resources.

    NICE has published final draft guidance that does not recommend Enhertu (also called trastuzumab deruxtecan and made by Daiichi Sankyo) for treating advanced HER2-low breast cancer in adults.

    News
    Published
    6 March 2024

  40. Early and locally advanced breast cancer: diagnosis and treatment (CG80)

    This guideline has been updated and replaced by NICE guideline NG101.

    Clinical guideline
    Last updated
    22 March 2017

  41. Guidance on the use of vinorelbine for the treatment of advanced breast cancer (TA54)

    This guidance has been updated and replaced by NICE guideline CG81.

    Technology appraisal guidance
    Published
    13 December 2002

  42. Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593)

    This guidance has been updated and replaced by NICE technology appraisal guidance 687.

    Technology appraisal guidance
    Published
    14 August 2019

  43. Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA619)

    This guidance has been updated and replaced by NICE technology appraisal guidance 836.

    Technology appraisal guidance
    Published
    15 January 2020

  44. Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal) (TA652)

    This guidance has been updated and replaced by NICE technology appraisal guidance 816.

    Technology appraisal guidance
    Published
    7 October 2020

  45. 300 people to benefit from new treatment for advanced breast cancer recommended by NICE following price deal

    Around 300 people are set to benefit following NICE’s recommendation of talazoparib for treating a type of locally advanced or metastatic breast cancer in final draft guidance published today (19 January 2024).

    News
    Published
    19 January 2024

  46. NICE draft guidance recognises potential of new targeted treatment for type of advanced breast cancer

    NICE has today (26 September 2023) published draft guidance for public consultation that does not recommend trastuzumab deruxtecan for treating advanced HER2-low breast cancer in adults.

    News
    Published
    26 September 2023

  47. Reducing radiotherapy for some breast cancer patients is likely to have released thousands of appointments for the NHS without compromising safety, NICE finds.

    Delivering fewer radiotherapy sessions over a shorter period of time, first introduced during COVID, benefits patients and the system long-term and is now enshrined in NICE guidance.

    News
    Published
    14 June 2023

  48. Improved deal means new treatment for a type of advanced breast cancer can be recommended by NICE

    Draft guidance published today (22 May 2020) by NICE recommends atezolizumab for treating people with a type of breast cancer, called triple negative breast cancer, that has spread to other parts of the body.

    News
    Published
    22 May 2020

  49. New injectable immunotherapy treatment for rare form of triple negative breast cancer recommended by NICE

    An estimated 100 people per year with triple negative breast cancer that has spread to other parts of the body may soon benefit from pembrolizumab in combination with chemotherapy (paclitaxel or nab-paclitaxel) following the final draft recommendation from NICE.

    News
    Published
    25 May 2022

  50. NICE draft guidance does not recommend tucatinib for advanced breast cancer

    NICE has today (26 October) published draft guidance for public consultation which does not recommend tucatinib (also called TUKYSA and made by Seagen Inc), in combination with trastuzumab and capecitabine, for some types of breast cancer that has spread.

    News
    Published
    26 October 2021